Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Alaska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 12 | 699 | 2% |
| 2020 | 10 | 639 | 2% |
| 2021 | 11 | 645 |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Alaska; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 375 | 24,956+2.5%/yr | +2.5%/yr | 7.1 | 86% | 32,700 in 2030+4.6%/yr |
| Arizona | 185 |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Alaska · Every state · Compare with California
| ≈ 710 |
| – |
| 2026 est. | ≈ 720 | – |
| 2% |
| 2022 | 7 | 508 | 3% |
| 2023 | 8 | 494 | 3% |
| 2024 | 10 | 623 | 3% |
| 2025 from claims | – | 709 573–832 | 3% |
| 2026 forecast | – | 723 566–908 | 3% |
| 2027 forecast | – | 736 546–973 | 3% |
| 2028 forecast | – | 749 531–1,034 | 3% |
| 2029 forecast | – | 763 519–1,094 | 3% |
| 2030 forecast | – | 777 509–1,153 | 3% |
In 2025, 8% hospital outpatient, 34% surgery center, 59% office. The share outside the hospital has moved −8 pts since 2019.
| 17,395+0.3%/yr |
| +0.3%/yr |
| 22.4 |
| 93% |
| 19,600 in 2030+2%/yr |
| Utah | 70 | 6,327+1.2%/yr | +1.2%/yr | 27.5 | 82% | 7,570 in 2030+3%/yr |
| Colorado | 95 | 6,258+2.1%/yr | +2.1%/yr | 12.2 | 84% | 8,230 in 2030+4.7%/yr |
| Washington | 75 | 4,700−0.3%/yr | −0.3%/yr | 5.9 | 77% | 5,550 in 2030+2.8%/yr |
| Nevada | 54 | 3,899−4.7%/yr | −4.7%/yr | 12.9 | 98% | 4,350 in 2030+1.8%/yr |
| Oregon | 49 | 3,673+3.6%/yr | +3.6%/yr | 8.3 | 97% | 5,130 in 2030+5.7%/yr |
| New Mexico | 39 | 2,542+2.5%/yr | +2.5%/yr | 10.5 | 73% | 3,290 in 2030+4.4%/yr |
| Idaho | 27 | 2,085+4.8%/yr | +4.8%/yr | 9.8 | 42% | 3,470 in 2030+8.9%/yr |
| Montana | 25 | 973−0.6%/yr | −0.6%/yr | 5.0 | 49% | 1,190 in 2030+3.4%/yr |
| Wyoming | 5 | 424+10%/yr | +10%/yr | 3.8 | 51% | 1,010 in 2030+16%/yr |
| Hawaii | 2 | 164−13%/yr | −13%/yr | 1.2 | 95% | 250 in 2030+7.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 69% of company spending on these surgeons in 2025, +23 pts on 2024.
In 2025, 4 companies reported engagement with Alaska’s surgeons worth $2,505 in consulting, speaking, meals and travel tied to these products, about $250 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.